Peter Rhode - HCW Biologics Chief Operations
| HCWB Stock | USD 0.61 0.16 20.78% |
Insider
Peter Rhode is Chief Operations of HCW Biologics
| Age | 66 |
| Address | 2929 North Commerce Parkway, Miramar, FL, United States, 33025 |
| Phone | 954 842 2024 |
| Web | https://www.hcwbiologics.com |
Peter Rhode Latest Insider Activity
Tracking and analyzing the buying and selling activities of Peter Rhode against HCW Biologics stock is an integral part of due diligence when investing in HCW Biologics. Peter Rhode insider activity provides valuable insight into whether HCW Biologics is net buyers or sellers over its current business cycle. Note, HCW Biologics insiders must abide by specific rules, including filing SEC forms every time they buy or sell HCW Biologics'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Peter Rhode over a year ago Exercise or conversion by Peter Rhode of 15000 shares of HCW Biologics subject to Rule 16b-3 |
HCW Biologics Management Efficiency
The company has return on total asset (ROA) of (0.7009) % which means that it has lost $0.7009 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (3.4432) %, meaning that it created substantial loss on money invested by shareholders. HCW Biologics' management efficiency ratios could be used to measure how well HCW Biologics manages its routine affairs as well as how well it operates its assets and liabilities. As of November 26, 2024, Return On Tangible Assets is expected to decline to -0.92. In addition to that, Return On Capital Employed is expected to decline to -1.37. At present, HCW Biologics' Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Net Tangible Assets is expected to grow to about 45.2 M, whereas Non Current Assets Total are forecasted to decline to about 11.7 M.Similar Executives
| Showing other executives | INSIDER Age | ||
| Jeff York | Seres Therapeutics | N/A | |
| Robert MBA | Eliem Therapeutics | 56 | |
| Kristin Ainsworth | Seres Therapeutics | N/A | |
| Bradley JD | Lumos Pharma | 45 | |
| Erin Lavelle | Eliem Therapeutics | 47 | |
| James JD | Eliem Therapeutics | 58 | |
| Lisa Miller | Lumos Pharma | N/A | |
| FACC FAHA | Milestone Pharmaceuticals | 66 | |
| David MBA | Seres Therapeutics | 63 | |
| Susan MS | Eliem Therapeutics | N/A | |
| MBA MD | Eliem Therapeutics | 63 | |
| Richard Hawkins | Lumos Pharma | 75 | |
| BBA CPA | Lumos Pharma | 57 | |
| FACC MD | Milestone Pharmaceuticals | 60 | |
| Lorenz Muller | Milestone Pharmaceuticals | 60 | |
| Carl Langren | Lumos Pharma | 69 | |
| MD BA | Lumos Pharma | 69 | |
| Philippe MBA | Milestone Pharmaceuticals | 62 | |
| Katherine Taudvin | Scpharmaceuticals | N/A | |
| Lori CPA | Lumos Pharma | 40 | |
| Kimberly Sheehan | Milestone Pharmaceuticals | N/A | |
Management Performance
| Return On Equity | -3.44 | ||||
| Return On Asset | -0.7 |
HCW Biologics Leadership Team
Elected by the shareholders, the HCW Biologics' board of directors comprises two types of representatives: HCW Biologics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of HCW. The board's role is to monitor HCW Biologics' management team and ensure that shareholders' interests are well served. HCW Biologics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, HCW Biologics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Hing Wong, CEO, Founder | ||
| Lee Flowers, Senior Development | ||
| Peter Rhode, Chief Operations | ||
| Nicole Esq, Vice Affairs | ||
| Raquel MS, Director Resources |
HCW Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is HCW Biologics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -3.44 | ||||
| Return On Asset | -0.7 | ||||
| Operating Margin | (22.36) % | ||||
| Current Valuation | 37.32 M | ||||
| Shares Outstanding | 37.82 M | ||||
| Shares Owned By Insiders | 52.30 % | ||||
| Shares Owned By Institutions | 3.10 % | ||||
| Number Of Shares Shorted | 8.09 K | ||||
| Price To Book | 2.80 X | ||||
| Price To Sales | 6.51 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether HCW Biologics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of HCW Biologics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Hcw Biologics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Hcw Biologics Stock:Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in HCW Biologics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in housing. For information on how to trade HCW Stock refer to our How to Trade HCW Stock guide.You can also try the Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of HCW Biologics. If investors know HCW will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about HCW Biologics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.05) | Revenue Per Share 0.107 | Quarterly Revenue Growth (0.01) | Return On Assets (0.70) | Return On Equity (3.44) |
The market value of HCW Biologics is measured differently than its book value, which is the value of HCW that is recorded on the company's balance sheet. Investors also form their own opinion of HCW Biologics' value that differs from its market value or its book value, called intrinsic value, which is HCW Biologics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because HCW Biologics' market value can be influenced by many factors that don't directly affect HCW Biologics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between HCW Biologics' value and its price as these two are different measures arrived at by different means. Investors typically determine if HCW Biologics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, HCW Biologics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.